Neurocognitive Features of Patients With Treatment-Resistant Depression

Brief Summary

There is an urgent need for novel and effective interventions for treatment-resistant depression (TRD). In previous studies, ketamine has been shown to rapidly reduce depressive symptoms; however, the exact mechanisms of action of ketamine remain unknown. There are some preliminary findings to suggest that ketamine may exert its antidepressant effects through promotion of neurogenesis in the dentate gyrus. The aim of this study is to help delineate the neurocognitive effects of ketamine exposure using a behavioral task (specifically, a pattern separation task) and a battery of other well-established cognitive measures.

This is an assessment-only study, as we will be recruiting subjects to complete an assessment battery at two time points, before and after receiving ongoing ketamine administrations for at least four weeks.

Intervention / Treatment

Condition or Disease

  • Treatment Resistant Depression

Phase

Study Design

Study type: Observational
Status: Completed
Study results: No Results Available
Age: 18 Years to 80 Years   (Adult, Older Adult)
Enrollment: 13 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Sep 16, 2020
Primary Completion: Aug 09, 2017
Completion Date: Jan 17, 2018
Study First Posted: Apr 28, 2017
Results First Posted: Aug 31, 2020
Last Updated: Mar 11, 2020

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 80

More Details

NCT Number: NCT03134066
Other IDs: 2016P001654
Study URL: https://ClinicalTrials.gov/show/NCT03134066
Last updated: Jan 27, 2021